Exactitude Consultancy
Home Report Store Categories Primary Research Consulting Services Blog Contact us About Us Terms & Conditions Privacy Policy

Global Immunotherapy Drugs Market

Apr 2023

Base Year Value ()

x.x %
x.x %

CAGR ()

x.x %
x.x %

Forecast Year Value ()

x.x %
x.x %

Historical Data Period

Largest Region

Forecast Period

Global Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Immunomodulators, Interlukins, Vaccines), by Therapy Area (Cancer, Autoimmune Disease, Inflammatory Disease, Infectious Disease), by End User (Hospital, Clinic) and by Region, Global trends and forecast from 2022 to 2029.

Instant access to hundreds of data points and trends

  • Market estimates from 2014-2029
  • Competitive analysis, industry segmentation, financial benchmarks
  • Incorporates SWOT, Porter's Five Forces and risk management frameworks
  • PDF report or online database with Word, Excel and PowerPoint export options
  • 100% money back guarantee

Global Immunotherapy Drugs Market Overview


The global Immunotherapy drugs market size is expected to grow at more than 11.27% CAGR from 2021 to 2029. It is expected to reach above USD 423.48 billion by 2029 from a little above USD 161.97 billion in 2020.  

Drugs used in immunotherapy are used to either strengthen or weaken the immune system of the body. They primarily fight cancer by boosting the immune system and causing an immunological reaction that promotes the production of antibodies. Malignant or tumor cells are destroyed by antibodies that are produced in response to an antigen. The market's revenue growth is primarily being driven by an increase in the number of successful Research & Development (R&D) outcomes in the field of immunotherapy used to treat cancer, autoimmune diseases, neurodegenerative diseases, adenocarcinomas, cardiovascular diseases, and other diseases, as well as rising adoption of targeted therapy over traditional therapy and an increase in the prevalence of chronic diseases and lifestyle disorders. Immunotherapy is a form of biological therapy used to treat cancer patients. It works by enhancing the patient's immune system's capacity to find and destroy cancer cells within the body.






















































ATTRIBUTE DETAILS
Study period 2020-2029
Base year 2021
Estimated year 2022
Forecasted year 2022-2029
Historical period 2018-2020
Unit Value (USD Billion), (Thousand Units)
Segmentation By Type, By Therapy Area, By End User, By Region
By Type

  • Monoclonal Antibodies

  • Immunomodulators

  • Interlukins

  • Vaccines


By Therapy Area

  • Cancer

  • Autoimmune Disease

  • Inflammatory Disease

  • Infectious Disease


By End User

  • Hospital

  • Clinic


By Region

  • North America

  • Asia Pacific

  • Europe

  • South America

  • Middle East Asia & Africa



 

Immunotherapies that focus on immunomodulation, passive viral neutralization, and inflammatory cytokine neutralization can lower viral load, prevent ICU admission, and reduce inflammation-related lung damage while also reducing inflammation itself. This will help the market expand more quickly. Because they enable the development of antibodies that specifically target a particular tumor antigen, monoclonal antibodies are advantageous. The antibodies can be produced in large quantities using in vitro methods in the lab. Another factor that will support the expansion of the market is the necessity of biosimilars in the treatment of cancer. In addition, the future growth of the market for immunotherapy pharmaceuticals may be influenced by the rising desire for customized treatment and the development of more accessible nanoparticles for immunotherapies.


COVID-19 had significant positive impact on the immunotherapy drug market. Market share for immunotherapy drugs increased as a result of COVID-19. The impact of COVID-19 on the industry for immunotherapy treatments is favorable due to the fact that multiple companies are actively working on developing immunotherapy-based drugs or vaccines for COVID-19. In collaboration with Pfizer Inc., BioNTech SE is presently conducting phase III clinical research in healthy volunteers to evaluate the safety, tolerability, and immunogenicity of BNT162b2 against COVID-19.




[caption id="attachment_15053" align="aligncenter" width="1920"]Immunotherapy Drugs Market | Exactitude Consultancy
Immunotherapy Drugs Market | Exactitude Consultancy
[/caption]

Frequently Asked Questions

• Who are the key players in the global immunotherapy drugs market?

Some key players operating in the global immunotherapy drugs market include Amgen Inc., Novartis AG, AbbVie Inc., Pfizer Inc., Nextera AS, Johnson & Johnson Services Inc., AstraZeneca, GSK, Sanofi, Biomunex Pharmaceuticals.

• What are the factors driving the global immunotherapy drugs market?

The market's revenue growth is primarily being driven by an increase in the number of successful Research & Development (R&D) outcomes in the field of immunotherapy used to treat cancer, autoimmune diseases, neurodegenerative diseases, adenocarcinomas, cardiovascular diseases, and other diseases, as well as rising adoption of targeted therapy over traditional therapy and an increase in the prevalence of chronic diseases and lifestyle disorders.

• How big is the global immunotherapy drugs market?

The global Immunotherapy Drugs market size was estimated at USD 161.97 billion in 2021 and is expected to reach USD 423.48 billion in 2029.

• What is the global immunotherapy drugs market growth?

The global immunotherapy drugs market is expected to grow at a compound annual growth rate of 11.27 % from 2022 to 2029 to reach USD 423.48 billion by 2029.

• Which region accounted for the largest global immunotherapy drugs market share?

The North America dominated the global immunotherapy drugs market with a share of 34% in 2021.

Global Immunotherapy Drugs Market Segment Analysis

Based on the type, market is segmented into monoclonal antibodies, immunomodulators, interlukins, vaccines. The monoclonal antibodies segment account for the maximum share of market revenue due to its improved implementation in cancer immunotherapy. It frequently has fewer side effects than other cancer treatments and helps the immune system fight cancer. Revenue growth in this market is being driven by immunomodulators' notable accuracy in preventing cancer when compared to other techniques. These are substances that either stimulate newly developed immune responses or boost already existing ones in order to identify and eradicate cancer cells.

Based on the therapy area, market is segmented into cancer, autoimmune disease, inflammatory disease, infectious disease. Cancer treatment accounted for largest use of immunotherapy drugs. One of the main factors influencing this segment's revenue growth is the rising incidence of cancer around the world, which is being accompanied by a shift away from chemotherapy due to its adverse effects. An enormous increase in the quantity of successful R&D (Research and Development) efforts is being caused by the rising prevalence of autoimmune illnesses.

By end user, market is segmented into hospital and clinic. Hospitals account for the major share for the use of immunotherapy drugs.

[caption id="attachment_15054" align="aligncenter" width="1920"]Immunotherapy Drugs Market | Exactitude Consultancy
Immunotherapy Drugs Market | Exactitude Consultancy
[/caption]

Global Immunotherapy Drugs Market Players

Key competitors from both domestic and international markets compete fiercely in the worldwide global Immunotherapy Drugs industry include Amgen Inc., Novartis AG, AbbVie Inc., Pfizer Inc., Nextera AS, Johnson & Johnson Services Inc., AstraZeneca, GSK, Sanofi, Biomunex Pharmaceuticals. Recent News:
  • 20th March 2022: Nextera AS strategically collaborated with Zelluna Immunotherapy AS for the development of optimized TCRs for cancer immunotherapy.
  • February 2022: Biomunex Pharmaceuticals collaborated with Institut Curie to develop an immunotherapy drug candidate to treat hematological malignancies using Biomunex’ BiXAR technology.

Who Should Buy? Or Key stakeholders

  • Immunotherapy Drugs Providers
  • Research and Development Organizations
  • Regulatory Agencies
  • Specialties Pharmacy
  • Cancer Clinics
  • Pharmaceutical Manufactures
  • Investors
  • Others

Global Immunotherapy Drugs Market Regional Analysis

The Global Immunotherapy Drugs Market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).

  • North America: includes the US, Canada, Mexico
  • Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN and Rest of APAC
  • Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
  • South America: includes Brazil, Argentina and Rest of South America
  • Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA
[caption id="attachment_15055" align="aligncenter" width="1920"]Immunotherapy Drugs Market | Exactitude Consultancy
Immunotherapy Drugs Market | Exactitude Consultancy
[/caption]

Due to an increase in FDA approvals, North America currently holds a monopoly on the market for immunotherapy medications. Additionally, throughout the projected period, the prevalence of autoimmune disorders and cancer will increase, which will further support the expansion of the market for immunotherapy drugs in the area. Due to the rising costs of building a healthcare infrastructure, the immunotherapy medicine market in Asia-Pacific is expected to grow significantly throughout this period. Furthermore, it is projected that in the upcoming years, the market for immunotherapy medications in the region will rise significantly due to the large patient pool and rising cancer incidence.

Key Market Segments: Global Immunotherapy Drugs Market

Global Immunotherapy Drugs Market By Type, 2020-2029, (USD Billion), (Thousand Units)
  • Monoclonal Antibodies
  • Immunomodulators
  • Interlukins
  • Vaccines
Global Immunotherapy Drugs Market By Therapy Area, 2020-2029, (USD Billion), (Thousand Units)
  • Cancer
  • Autoimmune Disease
  • Inflammatory Disease
  • Infectious Disease
Global Immunotherapy Drugs Market By End User, 2020-2029, (USD Billion), (Thousand Units)
  • Hospital
  • Clinic
Global Immunotherapy Drugs Market By Region, 2020-2029, (USD Billion), (Thousand Units)
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East And Africa
Important Countries In All Regions Are Covered

Exactitude Consultancy Services Key Objectives

  • Increasing sales and market share
  • Developing new technology
  • Improving profitability
  • Entering new market
  • Enhancing brand reputation

Key Question Answered

  • What is the expected growth rate of the immunotherapy drugs market over the next 7 years?
  • Who are the major players in the immunotherapy drugs market and what is their market share?
  • What are the end-user industries driving demand for market and what is their outlook?
  • What are the opportunities for growth in emerging markets such as Asia-Pacific, Middle East, and Africa?
  • How is the economic environment affecting the immunotherapy drugs market, including factors such as interest rates, inflation, and exchange rates?
  • What is the expected impact of government policies and regulations on the immunotherapy drugs market?
  • What is the current and forecasted size and growth rate of the global immunotherapy drugs market?
  • What are the key drivers of growth in the immunotherapy drugs market?
  • What are the distribution channels and supply chain dynamics in the immunotherapy drugs market?
  • What are the technological advancements and innovations in the immunotherapy drugs market and their impact on product development and growth?
  • What are the regulatory considerations and their impact on the market?
  • What are the challenges faced by players in the immunotherapy drugs market and how are they addressing these challenges?
  • What are the opportunities for growth and expansion in the immunotherapy drugs market?
  • What are the product offerings and specifications of leading players in the market?
  • What is the pricing trend of immunotherapy drugs’ in the market and what is the impact of raw material prices on the price trend?

  1. INTRODUCTION

    1. MARKET DEFINITION

    2. MARKET SEGMENTATION

    3. RESEARCH TIMELINES

    4. ASSUMPTIONS AND LIMITATIONS



  2. RESEARCH METHODOLOGY

    1. DATA MINING

      1. SECONDARY RESEARCH

      2. PRIMARY RESEARCH

      3. SUBJECT-MATTER EXPERTS’ ADVICE



    2. QUALITY CHECKS

      1. FINAL REVIEW



    3. DATA TRIANGULATION

      1. BOTTOM-UP APPROACH

      2. TOP-DOWN APPROACH

      3. RESEARCH FLOW



    4. DATA SOURCES



  3. EXECUTIVE SUMMARY

  4. MARKET OVERVIEW

    1. GLOBAL IMMUNOTHERAPY DRUGS MARKET OUTLOOK

      1. MARKET DRIVERS

      2. MARKET RESTRAINTS

      3. MARKET OPPORTUNITIES



    2. IMPACT OF COVID-19 ON IMMUNOTHERAPY DRUGS MARKET

    3. PORTER’S FIVE FORCES MODEL

      1. THREAT FROM NEW ENTRANTS

      2. THREAT FROM SUBSTITUTES

      3. BARGAINING POWER OF SUPPLIERS

      4. BARGAINING POWER OF CUSTOMERS

      5. DEGREE OF COMPETITION



    4. INDUSTRY VALUE CHAIN ANALYSIS



  5. GLOBAL IMMUNOTHERAPY DRUGS MARKET BY TYPE, 2020-2029, (USD BILLION), (THOUSAND UNITS)

    1. MONOCLONAL ANTIBODIES

    2. IMMUNOMODULATORS

    3. INTERLUKINS

    4. VACCINES



  6. GLOBAL IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA, 2020-2029, (USD BILLION), (THOUSAND UNITS)

    1. CANCER

    2. AUTOIMMUNE DISEASE

    3. INFLAMMATORY DISEASE

    4. INFECTIOUS DISEASE



  7. GLOBAL IMMUNOTHERAPY DRUGS MARKET BY END USER, 2020-2029, (USD BILLION), (THOUSAND UNITS)

    1. HOSPITAL

    2. CLINIC



  8. GLOBAL IMMUNOTHERAPY DRUGS MARKET BY REGION, 2020-2029, (USD BILLION), (THOUSAND UNITS)

    1. NORTH AMERICA

      1. US

      2. CANADA

      3. MEXICO



    2. SOUTH AMERICA

      1. BRAZIL

      2. ARGENTINA

      3. COLOMBIA

      4. REST OF SOUTH AMERICA



    3. EUROPE

      1. GERMANY

      2. UK

      3. FRANCE

      4. ITALY

      5. SPAIN

      6. RUSSIA

      7. REST OF EUROPE



    4. ASIA PACIFIC

      1. INDIA

      2. CHINA

      3. JAPAN

      4. SOUTH KOREA

      5. AUSTRALIA

      6. SOUTH-EAST ASIA

      7. REST OF ASIA PACIFIC



    5. MIDDLE EAST AND AFRICA

      1. UAE

      2. SAUDI ARABIA

      3. SOUTH AFRICA

      4. REST OF MIDDLE EAST AND AFRICA






    9. COMPANY PROFILES*  (BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCTS OFFERED, RECENT DEVELOPMENTS)

  1. AMGEN INC.

  2. NOVARTIS AG

  3. ABBVIE INC.

  4. PFIZER INC.

  5. NEXTERA AS

  6. JOHNSON & JOHNSON SERVICES INC.

  7. ASTRAZENECA

  8. GSK

  9. SANOFI

  10. BIOMUNEX PHARMACEUTICALS *THE COMPANY LIST IS INDICATIVE


LIST OF TABLES


TABLE 1 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 2 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 3 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 4 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 5 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 6 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 7 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY REGION (USD BILLION) 2020-2029

TABLE 8 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY REGION (THOUSAND UNITS) 2020-2029

TABLE 9 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 10 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY COUNTRY (THOUSAND UNITS) 2020-2029

TABLE 11 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 12 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 13 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 14 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 15 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 16 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 17 US IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 18 US IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 19 US IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 20 US IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 21 US IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 22 US IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 23 CANADA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 24 CANADA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 25 CANADA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 26 CANADA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 27 CANADA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 28 CANADA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 29 MEXICO IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 30 MEXICO IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 31 MEXICO IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 32 MEXICO IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 33 MEXICO IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 34 MEXICO IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 35 SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 36 SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY COUNTRY (THOUSAND UNITS) 2020-2029

TABLE 37 SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 38 SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 39 SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 40 SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 41 SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 42 SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 43 BRAZIL IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 44 BRAZIL IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 45 BRAZIL IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 46 BRAZIL IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 47 BRAZIL IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 48 BRAZIL IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 49 ARGENTINA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 50 ARGENTINA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 51 ARGENTINA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 52 ARGENTINA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 53 ARGENTINA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 54 ARGENTINA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 55 COLOMBIA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 56 COLOMBIA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 57 COLOMBIA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 58 COLOMBIA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 59 COLOMBIA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 60 COLOMBIA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 61 REST OF SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 62 REST OF SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 63 REST OF SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 64 REST OF SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 65 REST OF SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 66 REST OF SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 67 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 68 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY COUNTRY (THOUSAND UNITS) 2020-2029

TABLE 69 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 70 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 71 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 72 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 73 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 74 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 75 INDIA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 76 INDIA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 77 INDIA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 78 INDIA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 79 INDIA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 80 INDIA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 81 CHINA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 82 CHINA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 83 CHINA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 84 CHINA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 85 CHINA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 86 CHINA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 87 JAPAN IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 88 JAPAN IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 89 JAPAN IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 90 JAPAN IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 91 JAPAN IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 92 JAPAN IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 93 SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 94 SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 95 SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 96 SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 97 SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 98 SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 99 AUSTRALIA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 100 AUSTRALIA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 101 AUSTRALIA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 102 AUSTRALIA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 103 AUSTRALIA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 104 AUSTRALIA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 105 SOUTH-EAST ASIA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 106 SOUTH-EAST ASIA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 107 SOUTH-EAST ASIA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 108 SOUTH-EAST ASIA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 109 SOUTH-EAST ASIA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 110 SOUTH-EAST ASIA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 111 REST OF ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 112 REST OF ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 113 REST OF ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 114 REST OF ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 115 REST OF ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 116 REST OF ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 117 EUROPE IMMUNOTHERAPY DRUGS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 118 EUROPE IMMUNOTHERAPY DRUGS MARKET BY COUNTRY (THOUSAND UNITS) 2020-2029

TABLE 119 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 120 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 121 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 122 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 123 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 124 ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 125 GERMANY IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 126 GERMANY IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 127 GERMANY IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 128 GERMANY IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 129 GERMANY IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 130 GERMANY IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 131 UK IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 132 UK IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 133 UK IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 134 UK IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 135 UK IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 136 UK IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 137 FRANCE IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 138 FRANCE IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 139 FRANCE IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 140 FRANCE IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 141 FRANCE IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 142 FRANCE IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 143 ITALY IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 144 ITALY IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 145 ITALY IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 146 ITALY IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 147 ITALY IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 148 ITALY IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 149 SPAIN IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 150 SPAIN IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 151 SPAIN IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 152 SPAIN IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 153 SPAIN IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 154 SPAIN IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 155 RUSSIA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 156 RUSSIA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 157 RUSSIA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 158 RUSSIA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 159 RUSSIA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 160 RUSSIA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 161 REST OF EUROPE IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 162 REST OF EUROPE IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 163 REST OF EUROPE IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 164 REST OF EUROPE IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 165 REST OF EUROPE IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 166 REST OF EUROPE IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 167 MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY COUNTRY (USD BILLION) 2020-2029

TABLE 168 MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY COUNTRY (THOUSAND UNITS) 2020-2029

TABLE 169 MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 170 MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 171 MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 172 MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 173 MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 174 MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 175 UAE IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 176 UAE IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 177 UAE IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 178 UAE IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 179 UAE IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 180 UAE IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 181 SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 182 SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 183 SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 184 SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 185 SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 186 SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 187 SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 188 SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 189 SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 190 SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 191 SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 192 SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

TABLE 193 REST OF MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY TYPE (USD BILLION) 2020-2029

TABLE 194 REST OF MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY TYPE (THOUSAND UNITS) 2020-2029

TABLE 195 REST OF MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (USD BILLION) 2020-2029

TABLE 196 REST OF MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA (THOUSAND UNITS) 2020-2029

TABLE 197 REST OF MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY END USER (USD BILLION) 2020-2029

TABLE 198 REST OF MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET BY END USER (THOUSAND UNITS) 2020-2029

LIST OF FIGURES


FIGURE 1 MARKET DYNAMICS

FIGURE 2 MARKET SEGMENTATION

FIGURE 3 REPORT TIMELINES: YEARS CONSIDERED

FIGURE 4 DATA TRIANGULATION

FIGURE 5 BOTTOM-UP APPROACH

FIGURE 6 TOP-DOWN APPROACH

FIGURE 7 RESEARCH FLOW

FIGURE 8 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY TYPE, USD BILLION, 2020-2029

FIGURE 9 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA, USD BILLION, 2020-2029

FIGURE 10 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY END USER, USD BILLION, 2020-2029

FIGURE 11 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY REGION, USD BILLION, 2020-2029

FIGURE 12 PORTER’S FIVE FORCES MODEL

FIGURE 13 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY TYPE, USD BILLION, 2021

FIGURE 14 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY THERAPY AREA, USD BILLION, 2021

FIGURE 15 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY END USER, USD BILLION, 2021

FIGURE 16 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY REGION, USD BILLION, 2021

FIGURE 17 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIGURE 18 EUROPE IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIGURE 19 SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIGURE 20 ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIGURE 21 MIDDLE EAST ASIA AND AFRICA IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIGURE 22 MARKET SHARE ANALYSIS

FIGURE 23 AMGEN: COMPANY SNAPSHOT

FIGURE 24 NOVARTIS AG: COMPANY SNAPSHOT

FIGURE 25 ABBVIE INC.: COMPANY SNAPSHOT

FIGURE 26 PFIZER INC.: COMPANY SNAPSHOT

FIGURE 27 F. HOFFMAN-LA ROCHE LTD.: COMPANY SNAPSHOT

FIGURE 28 JOHNSON & JOHNSON SERVICES INC.: COMPANY SNAPSHOT

FIGURE 29 ASTAZENECA: COMPANY SNAPSHOT

FIGURE 30 GSK: COMPANY SNAPSHOT

FIGURE 31 SANOFI: COMPANY SNAPSHOT

FIGURE 32 BAYER AG: COMPANY SNAPSHOT

DOWNLOAD FREE SAMPLE REPORT

Kindly share your specific requirement (if any)
1432

License Type

Single User

US$ 3499

Multi User

US$ 4499

Corporate User

US$ 5499

Get Sample to Email

SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

WANT TO CUSTOMIZE THE REPORT?

Our Clients Speak

We asked them to research ‘ Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te

Yosuke Mitsui

Senior Associate Construction Equipment Sales & Marketing

We asked them to research ‘Equipment market’ all over the world, and their whole arrangement was helpful to us. thehealthanalytics.com insightful analysis and reports contributed to our current analysis and in creating a future strategy. Besides, the te

Yosuke Mitsui

Senior Associate Construction Equipment Sales & Marketing

Why choose us

Proactive

We manage our resources 24/7 to identify issues and address them before they become problems

Quality & Reliability

We are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach

6 Major regions and 40+ countries level analysis accomplished

Competitive Pricing

Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

In-Depth Database

In-Depth Database

Our Report’s database covers almost all topics of all regions over the Globe.

Recognised Publishing Sources

Recognised Publishing Sources

Tie ups with top publishers around the globe.

Customer Support

Customer Support

Complete pre and post sales support.

Safe & Secure

Safe & Secure

Complete secure payment process.